What this trial studies
This study aims to evaluate the impact of a structured education program delivered under midwife guidance on menopause-specific quality of life among women aged 45-55 undergoing natural menopause, and to assess the sustainability of its effects over time.
Conditions in scope
- Menopause
- Quality of Life
Interventions
- Structured Menopause Education Program (Behavioral) — The structured education program was developed by midwifery researchers and delivered face-to-face by a certified midwife over four weekly sessions. Each session lasted approximately 20-25 minutes and covered topics such as menopausal symptoms, lifestyle changes, and coping strategies. Educational materials…
Who can join
Women only · Ages 45 Years to 55 Years
Inclusion criteria
- Women aged 45-55
- Experiencing natural (non-surgical) menopause
- Literate and able to complete questionnaires
- No neurological or cognitive impairments
- Willing to participate and attend sessions
- Has access to phone/internet
Exclusion criteria
- Surgical menopause
- Hormonal disorders causing amenorrhea
- Current use of hormonal therapy or antidepressants
- Diagnosed psychiatric conditions
- Removal Criteria (if applicable):
- Did not attend at least 80% of sessions
- Lost to follow-up at 6 months
- Developed a new health issue affecting menopause
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Muş | CİTY | Hasköy Family Health Center | Unknown |
Status & timeline
- Overall status: Completed
- Study type: Interventional
- Phase: N/A
- Start date: 2024-04-01
- Primary completion: 2024-05-30
- Last update posted: 2025-05-20
- First posted: 2025-05-20
Sponsor & contact
Lead sponsor: Inonu University (Other)
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- Change in Menopause-Specific Quality of Life (MENQOL) Scores (Baseline (T1), 4 weeks after intervention (T2), and 6 months after intervention (T3))
Mean change in total and subscale scores of the Menopause-Specific Quality of Life Questionnaire (MENQOL) from baseline to 6-month follow-up. Higher scores indicate greater symptom severity and lower quality of life.The MENQOL total score ranges from 0 to 6. Higher scores indicate greater symptom severity and lower quality of life.
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT06979947 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.